Literature DB >> 10477906

In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates.

P S Chan1, L W Chan, J W Xuan, J L Chin, H L Choi, F L Chan.   

Abstract

BACKGROUND: The prostatic secretory protein of 94 amino acids (PSP94), also named beta-microseminoprotein, is one of the major proteins secreted by the human prostate. However, its value as a prognostic marker for prostate cancers is still under debate. The aim of the present study was to examine the expression pattern of this protein in fetal, pubertal, and aged human prostates.
METHODS: Nonisotopic in situ hybridization using a digoxigenin-labeled riboprobe for PSP94 and immunohistochemistry were used to demonstrate the expression of PSP94 in different regions or zones of fetal, pubertal, and adult human prostates. Its localization pattern was also compared with those of two other major secretory proteins, prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), by immunohistochemistry.
RESULTS: PSP94 mRNA and its protein were localized to the secretory epithelium of normal pubertal and adult human prostates. No hybridization signal and immunoreactivity of PSP94 were seen in fetal prostates at 6-7 months of gestation, whereas some glandular cells were positive to PSA and PAP immunostainings. In the adult prostates, PSP94 expression was intense in the acini in the peripheral zone, less intense in the transition zone, and variable in the central zone. Such a zonal expression pattern was more apparent in the pubertal prostates. However, no obvious differential expression pattern was observed in the immunohistochemistry of PAP and PSA, which showed a uniform staining of the secretory epithelia of the acini in all anatomic zones. The hybridization signals and immunoreactivity of PSP94 became reduced or lost in premalignant prostatic intraepithelial neoplastic lesions and different grades of prostatic carcinomas.
CONCLUSIONS: Fetal prostates at 6-7 months of gestation already synthesize PSA and PAP but not PSP94. The delayed expression of PSP94 appears to correlate with the development of the prostate gland. A differential expression pattern of PSP94 is demonstrated in different anatomical zones, showing that this protein is more expressed and synthesized in the acini in the peripheral zone than in the central and transition zones. However, such a zonal pattern is not seen in the immunohistochemistry of PSA and PAP. The present study also shows that PSP94 is downregulated in different grades of prostate cancers. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477906     DOI: 10.1002/(sici)1097-0045(19991001)41:2<99::aid-pros4>3.0.co;2-c

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  beta-Microseminoprotein binds CRISP-3 in human seminal plasma.

Authors:  Lene Udby; Ake Lundwall; Anders H Johnsen; Per Fernlund; Camilla Valtonen-André; Anna M Blom; Hans Lilja; Niels Borregaard; Lars Kjeldsen; Anders Bjartell
Journal:  Biochem Biophys Res Commun       Date:  2005-07-29       Impact factor: 3.575

2.  Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes.

Authors:  Laura E Pascal; Ricardo Z N Vêncio; Laura S Page; Emily S Liebeskind; Christina P Shadle; Pamela Troisch; Bruz Marzolf; Lawrence D True; Leroy E Hood; Alvin Y Liu
Journal:  BMC Cancer       Date:  2009-12-18       Impact factor: 4.430

3.  Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.

Authors:  Liesel M FitzGerald; Xiaotun Zhang; Suzanne Kolb; Erika M Kwon; Ying Ching Liew; Antonio Hurtado-Coll; Beatrice S Knudsen; Elaine A Ostrander; Janet L Stanford
Journal:  Hum Mutat       Date:  2012-10-04       Impact factor: 4.878

4.  MSMB gene variant alters the association between prostate cancer and number of sexual partners.

Authors:  Marni Stott-Miller; Jonathan L Wright; Janet L Stanford
Journal:  Prostate       Date:  2013-08-23       Impact factor: 4.104

5.  Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.

Authors:  Anders S Bjartell; Hikmat Al-Ahmadie; Angel M Serio; James A Eastham; Scott E Eggener; Samson W Fine; Lene Udby; William L Gerald; Andrew J Vickers; Hans Lilja; Victor E Reuter; Peter T Scardino
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

6.  The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.

Authors:  Hayley C Whitaker; Zsofia Kote-Jarai; Helen Ross-Adams; Anne Y Warren; Johanna Burge; Anne George; Elizabeth Bancroft; Sameer Jhavar; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Edward Saunders; Elizabeth Page; Anita Mitra; Gillian Mitchell; Geoffrey J Lindeman; D Gareth Evans; Ignacio Blanco; Catherine Mercer; Wendy S Rubinstein; Virginia Clowes; Fiona Douglas; Shirley Hodgson; Lisa Walker; Alan Donaldson; Louise Izatt; Huw Dorkins; Alison Male; Kathy Tucker; Alan Stapleton; Jimmy Lam; Judy Kirk; Hans Lilja; Douglas Easton; Colin Cooper; Rosalind Eeles; David E Neal
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

7.  Promoter Polymorphism (rs12770170, -184C/T) of Microseminoprotein, Beta as a Risk Factor for Benign Prostatic Hyperplasia in Korean Population.

Authors:  Ju Yeon Ban; Koo Han Yoo
Journal:  Int Neurourol J       Date:  2014-06-26       Impact factor: 2.835

8.  Genistein treatment duration effects biomarkers of cell motility in human prostate.

Authors:  Hu Zhang; Ryan Gordon; Wenqi Li; Ximing Yang; Abhinandan Pattanayak; Graham Fowler; Limin Zhang; William J Catalona; Yongzeng Ding; Li Xu; Xiaoke Huang; Borko Jovanovic; David L Kelly; Haowen Jiang; Raymond Bergan
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

9.  Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.

Authors:  Liisa Sjöblom; Outi Saramäki; Matti Annala; Katri Leinonen; Janika Nättinen; Teemu Tolonen; Tiina Wahlfors; Matti Nykter; G Steven Bova; Johanna Schleutker; Teuvo L J Tammela; Hans Lilja; Tapio Visakorpi
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.